These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 9258630)

  • 1. Drug administration in chronic liver disease.
    Westphal JF; Brogard JM
    Drug Saf; 1997 Jul; 17(1):47-73. PubMed ID: 9258630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.
    Naranjo CA; Busto U; Janecek E; Ruiz I; Roach CA; Kaplan K
    Br J Clin Pharmacol; 1983 Apr; 15(4):451-8. PubMed ID: 6849781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.
    Matzke GR; Frye RF
    Drug Saf; 1997 Mar; 16(3):205-31. PubMed ID: 9098657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
    Bosilkovska M; Walder B; Besson M; Daali Y; Desmeules J
    Drugs; 2012 Aug; 72(12):1645-69. PubMed ID: 22867045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of newer antibacterial agents in liver disease.
    Westphal JF; Brogard JM
    Clin Pharmacokinet; 1993 Jan; 24(1):46-58. PubMed ID: 8448972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hepatic insufficiency on pharmacokinetics and drug dosing.
    Verbeeck RK; Horsmans Y
    Pharm World Sci; 1998 Oct; 20(5):183-92. PubMed ID: 9820880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safe prescribing in patients with liver cirrhosis; 5 pitfalls].
    Weersink RA; Drenth JPH; Ter Borg F; Mulder MB; Taxis K; Borgsteede SD
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing medications in patients with decompensated liver cirrhosis.
    Amarapurkar DN
    Int J Hepatol; 2011; 2011():519526. PubMed ID: 21994861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.
    Shah RR
    Expert Opin Drug Saf; 2005 Jan; 4(1):103-28. PubMed ID: 15709902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: prescribing medications in patients with cirrhosis - a practical guide.
    Lewis JH; Stine JG
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1132-56. PubMed ID: 23638982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.
    Verbeeck RK
    Clin Pharmacokinet; 1990 Jul; 19(1):44-66. PubMed ID: 2199127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal failure, drug pharmacokinetics and drug action.
    Fabre J; Balant L
    Clin Pharmacokinet; 1976; 1(2):99-120. PubMed ID: 13956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torasemide. An update of its pharmacological properties and therapeutic efficacy.
    Dunn CJ; Fitton A; Brogden RN
    Drugs; 1995 Jan; 49(1):121-42. PubMed ID: 7705212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.